When A Clinical Trial Surfaces In An AI Chat, What Happens Next?

By Ross Jackson, consultant

When looking into what AI might bring to the field of clinical trials, much of the discussion – especially related to patient recruitment – has focused on two increasingly common questions: Will AI (and the recently developed AI health assistants) begin surfacing relevant clinical trials to patients? And what happens if conversational AI platforms introduce advertising?

Both questions matter (as outlined in two recent articles: Will New AI Health Assistants Suggest Clinical Trials To Inquiring Patients and What ChatGPT Ads Will Really Mean For Clinical Trials).

But these questions focus on exposure. The more consequential shift may lie in what happens after exposure. The competitive advantage will not lie in being surfaced – but in surviving interrogation.

AI is increasingly becoming the first interpreter of your trial – not the search engine that helps a patient find it or the landing page that hosts it but the conversational layer that explains it. This difference has structural implications for enrollment design, screening efficiency, and ultimately program predictability.

From Exposure To Interpretation

In the search and social media era, any patients that were looking for information about clinical trials discovered them through:

• Google queries
• social media ads
• patient advocacy sites
• physician referrals.

Intent formation was fragmented. A patient might:

• click multiple links
• compare summaries
• read protocol descriptions
• skim eligibility criteria
• visit forums or Reddit threads.

Decision-making took time, and scrutiny was distributed across multiple sources. Conversational AI compresses that journey. A user can now ask:

• “Would I qualify for this trial?”
• “How much time would it take?”
• “Is it risky?”
• “Is it better than my current treatment?”
• “What happens if I sign up?”
• “How far would I need to travel?”

They receive a synthesized answer in seconds. Awareness, clarification, objection handling, and comparison collapse into a single thread.

Decision Compression

Search and social media helped patients find trials; AI helps patients decide about trials. That distinction may sound subtle, but it’s actually profound.

Is This About Generative Engine Optimization (GEO)?

GEO is the term that has arisen for the practice of structuring information such that it can be surfaced within AI chat platforms such as ChatGPT, Claude, Gemini, etc.

The basic principles of GEO are:

• Direct answers – using clear, concise language
• Trust & authority – credible sources and data
• Content types – a variety of different types of content
• Tone – addressing a potential query directly

All are good principles to adopt for clarity and understanding – something our industry is perhaps lacking as its default position.

But GEO is not the full story.

Conversational marketing is an umbrella term for the practices of GEO and techniques that will help to surface relevant information within an AI chat. What happens then, though, is what I’m describing as “interrogable marketing” – how to ensure your information remains robust and engaging when a user interrogates their AI chat service about what has just been surfaced.

• GEO = surfacing discipline
• Conversational marketing = exposure mechanics
• Interrogable marketing = post-surfacing resilience

Why This Is Not Simply SEO Or Social Media Marketing In New Clothes

It would be easy to dismiss this shift as optimization under a new label. After all, good marketing has always emphasized:

• clear positioning
• specific claims
• objection handling
• structured FAQs
• frictionless conversion pathways.

Those principles remain. However, conversational AI introduces two structural changes that go beyond traditional search or social media optimization:

1. Loss of Narrative Primacy

In the search and social media era, the sponsor’s landing page was often the first authoritative explanation a patient encountered.

In the AI era, the first explanation may be machine-generated – synthesized from such things as ClinicalTrials.gov entries, protocol summaries, site pages, and other publicly available materials. (Most of which were never written to function as primary explanatory materials.)

If your communications are vague, overly technical, or fragmented, AI does not clarify them. It compresses them.

Interpretation becomes probabilistic.

The issue is no longer ranking. It is resilience under summarization.

2. Compressed Scrutiny

AI accelerates interrogation. Patients can challenge claims in real time:

• “Is this experimental?”
• “What are the side effects?”
• “What are the chances it works?”
• “Why wouldn’t I qualify?”
• “Is this worth it?”

The friction that once slowed inquiry – multiple clicks, scattered content, and long PDFs – has largely disappeared. Weak clarity is exposed earlier; strong clarity compounds faster. This compression changes how intent forms – and how quickly it dissolves.

The Four Pillars Of Interrogable Marketing

By interrogable marketing, I do not simply mean chat-enabled advertising. I mean designing clinical trial communications so that when AI systems interpret, summarize, and respond to patient questions, the resulting dialogue preserves clarity in four critical areas:

1. clarity of purpose
2. clarity of fit
3. clarity of trade-off
4. clarity of pathway

These are not AI tactics. They are structural disciplines that strengthen enrollment strategy. AI simply acts as a stress test.

Pillar 1. Clarity of Purpose

Most protocols can be described in scientific precision. Far fewer can be described in patient clarity. Consider the difference between:

Protocol language:
“A Phase 2 randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of XYZ-102 in adults with moderate to severe autoimmune dermatologic disease.”

Purpose clarity:
“We are testing whether XYZ-102 can reduce flare frequency in people whose current treatments are no longer working well enough.”

If AI struggles to summarize your trial in clear language, your coordinators and sites likely struggle as well. Clarity of purpose improves:

• initial engagement
• motivation to participate
• retention over time.

AI does not invent ambiguity. It exposes it.

Pillar 2. Clarity of Fit

Eligibility criteria are clinical. Fit is experiential. When a patient asks, “Is this for someone like me?” they are not reciting inclusion criteria. They are assessing personal relevance. Structured plain-language framing of fit, for example, would include:

• “adults aged 18–65”
• “at least two flare-ups in the past six months”
• “not currently on biologics.”

These details enable more accurate AI interpretation. This shifts self-selection upstream.

Why does that matter? Because improved self-selection reduces:

• screening failure
• site burden
• wasted contact attempts
• coordinator fatigue.

In capital-constrained environments, screening efficiency is not a tactical detail; it is a cost driver.

Pillar 3. Clarity of Trade-Off

Clinical trials involve trade-offs. Time. Effort. Risk. Monitoring. Uncertainty.

When burden is described vaguely – e.g., “participants will attend scheduled visits per protocol” – expectations misalign. Conversational AI will surface practical questions:

• “How many visits?”
• “How long are they?”
• “Will I need to stop my current treatment?”
• “How often are blood draws?”

If those answers are precise, trust forms faster. If they are fuzzy, doubt accelerates. Clarity of trade-off improves:

• consent stability
• mid-study retention
• site predictability.

Retention has economic consequences – replacing participants mid-trial is expensive.

Pillar 4. Clarity of Pathway

Perhaps the most underestimated variable in enrollment is what happens after interest is expressed. If AI-mediated inquiry leads a patient to believe

• they will be contacted within 48 hours,
• a coordinator will review eligibility, or

an appointment can be scheduled quickly, but in the real world, operational execution does not match that expectation, trust erodes.

Clear pathway design reduces:

• lead decay
• no-shows
• conversion volatility.

AI does not replace site execution; it accelerates expectation formation.

Clinical Trial Surfacing – Through Chat Or Ads

The central idea behind interrogable marketing holds true whether information about a clinical trial has been surfaced within an AI chat through the AI system’s own synthesizing of information or a contextual ad has been shown that AI deems relevant to the current conversation.

A Hypothetical Comparison

Consider two sponsors running similar Phase 2 studies. Both appear in AI-assisted chats (either as a chat response or a contextual ad). Sponsor A relies primarily on regulatory descriptions and protocol summaries. Sponsor B has structured plain-language summaries, clearly articulated fit criteria, transparent burden descriptions, and a defined contact pathway.

A patient asks an AI health assistant:

“Would this trial be right for me?”

Sponsor A’s explanation feels technical and uncertain.

Sponsor B’s explanation feels clear, specific, and predictable.

Which sponsor benefits from higher-quality intent?

The difference is not visibility. It is interrogation resilience.

The difference is not technological sophistication. It is clarity architecture.

Classical Marketing Principles, Reapplied

Interrogable marketing is not a completely new invention. The novelty is not in the principles. It is in the compression of scrutiny.

Claude Hopkins insisted on specificity.

John Caples emphasized clear audience targeting.

David Ogilvy argued for substance over vagueness.

All understood that ambiguity kills response. Conversational AI removes tolerance for ambiguity. If a claim cannot withstand interrogation, it collapses under compression.

AI does not reward volume. It rewards coherence. This is not about gaming algorithms. It is about building communications robust enough to survive machine interpretation.

Why This Matters To Biotech And Pharma Boards, Funders, And CEOs

Boards and funders do not invest in trends. They invest in predictability. If AI-mediated interpretation shifts:

• how quickly patients form intent,
• how accurately they self-select,
• how clearly expectations are set, or
• how efficiently sites convert,

then sponsors who adopt interrogation-ready clarity may experience

• lower screening failure rates,
• reduced site workload,
• faster enrollment velocity, and
• more stable timelines.

The impact may not appear dramatic at the individual interaction level, but across a global study, small improvements in upstream clarity can compound materially.

The Real Question

If tomorrow a patient asks an AI system about your trial, would the first explanation they receive:

• Be accurate?
• Be clear?
• Inspire confidence?
• Set realistic expectations?
• Support informed intent?

If the answer is uncertain, the issue is not AI readiness; it is clarity readiness. AI has not created a new marketing obligation. It has compressed scrutiny. Sponsors who design for interrogation will not win because of technology. They will win because their trials can withstand interpretation by human and machine. And in an era where intent forms faster than ever, that resilience may prove decisive, as clarity will no longer be a communications virtue. It becomes a risk variable.

About The Author:

Ross Jackson is a patient recruitment specialist and author of the books The Patient Recruitment Conundrum and Patient Recruitment for Clinical Trials using Facebook Ads.

Having started out with digital marketing in 1998, Ross quickly developed a specialty in the healthcare niche, evolving into a focus on clinical trials and the problems of patient recruitment and retention.

Over the years Ross branched out from the purely digital and now operates in an advisory capacity helping sponsors, CROs, sites, solutions providers, and others in the industry to improve their patient recruitment and retention capabilities — having advised and consulted on over 100 successful projects.